{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T18:26:54Z","timestamp":1774895214850,"version":"3.50.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T00:00:00Z","timestamp":1744070400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-025-00705-8","type":"journal-article","created":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T07:13:15Z","timestamp":1744096395000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Dual biological treatments in immune-mediated disorders: a single center experience"],"prefix":"10.1186","volume":"26","author":[{"given":"Oded","family":"Shamriz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elchanan","family":"Parnasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Limor","family":"Rubin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aviv","family":"Talmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaarit","family":"Ribak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isaam","family":"Hindi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hagit","family":"Peleg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronit","family":"Confino-Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuval","family":"Tal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,8]]},"reference":[{"issue":"2","key":"705_CR1","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.alit.2020.01.004","volume":"69","author":"Y Okayama","year":"2020","unstructured":"Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of Omalizumab in various allergic diseases. Allergol Int. 2020;69(2):167\u201377.","journal-title":"Allergol Int"},{"issue":"1","key":"705_CR2","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s12016-020-08794-6","volume":"59","author":"M Metz","year":"2020","unstructured":"Metz M, Vadasz Z, Kocaturk E, Gimenez-Arnau AM. Omalizumab updosing in chronic spontaneous urticaria: an overview of real-world evidence. Clin Rev Allergy Immunol. 2020;59(1):38\u201345.","journal-title":"Clin Rev Allergy Immunol"},{"key":"705_CR3","doi-asserted-by":"publisher","unstructured":"Normansell R, Walker S, Milan SJ, Walters EH, Nair P. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014(1):CD003559.\u00a0https:\/\/doi.org\/10.1002\/14651858.CD003559.pub4.","DOI":"10.1002\/14651858.CD003559.pub4"},{"issue":"1","key":"705_CR4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","volume":"50","author":"D El-Qutob","year":"2016","unstructured":"El-Qutob D. Off-label uses of Omalizumab. Clin Rev Allergy Immunol. 2016;50(1):84\u201396.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"1","key":"705_CR5","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cea.13491","volume":"50","author":"H Harb","year":"2020","unstructured":"Harb H, Chatila TA. Mechanisms of dupilumab. Clin Exp Allergy. 2020;50(1):5\u201314.","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"705_CR6","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1111\/jocd.15551","volume":"22","author":"A Abdelmaksoud","year":"2023","unstructured":"Abdelmaksoud A, Temiz SA, Daye M, Yavuz S, Wollina U, Lotti T, et al. Response of chronic refractory psoriasis vulgaris with urticaria to combined secukinumab and omalizumab: a case report and review of the literature. J Cosmet Dermatol. 2023;22(4):1416\u20138.","journal-title":"J Cosmet Dermatol."},{"issue":"4","key":"705_CR7","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1080\/09546634.2018.1515465","volume":"30","author":"MN Ghazanfar","year":"2019","unstructured":"Ghazanfar MN, Thomsen SF. Combined treatment with Omalizumab and etanercept in a patient with chronic spontaneous urticaria and rheumatoid arthritis. J Dermatolog Treat. 2019;30(4):387\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"705_CR8","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.ad.2021.02.029","volume":"113","author":"M Benko","year":"2022","unstructured":"Benko M, Hrvatin Stancic B, Lunder T. Two track biologic therapy for concurrent chronic spontaneous urticaria and psoriasis vulgaris in one patient. Actas Dermosifiliogr. 2022;113(10):995\u20136.","journal-title":"Actas Dermosifiliogr"},{"issue":"3","key":"705_CR9","first-page":"306","volume":"26","author":"HM Fox","year":"2021","unstructured":"Fox HM, Rotolo SM. Combination Anti-IgE and Anti-IL5 therapy in a pediatric patient with severe persistent asthma. J Pediatr Pharmacol Ther. 2021;26(3):306\u201310.","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"5","key":"705_CR10","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1080\/02770903.2018.1471706","volume":"56","author":"R Dedaj","year":"2019","unstructured":"Dedaj R, Unsel L. Case study: a combination of mepolizumab and Omaluzimab injections for severe asthma. J Asthma. 2019;56(5):473\u20134.","journal-title":"J Asthma"},{"issue":"4","key":"705_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.jaip.2017.01.013","volume":"5","author":"MC Altman","year":"2017","unstructured":"Altman MC, Lenington J, Bronson S, Ayars AG. Combination omalizumab and mepolizumab therapy for refractory allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol Pract. 2017;5(4):1137\u20139.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"11","key":"705_CR12","doi-asserted-by":"publisher","first-page":"100707","DOI":"10.1016\/j.waojou.2022.100707","volume":"15","author":"MM Pitlick","year":"2022","unstructured":"Pitlick MM, Pongdee T. Combining biologics targeting eosinophils (IL-5\/IL-5R), IgE, and IL-4\/IL-13 in allergic and inflammatory diseases. World Allergy Organ J. 2022;15(11):100707.","journal-title":"World Allergy Organ J"},{"key":"705_CR13","doi-asserted-by":"publisher","unstructured":"Baccelli A, Kocwin M, Parazzini EM, Rinaldo RF, Centanni S. Long-term outcomes of combination biologic therapy in uncontrolled severe asthma: a case study. J Asthma. 2022;60:1\u20134. https:\/\/doi.org\/10.1080\/02770903.2022.2109162.","DOI":"10.1080\/02770903.2022.2109162"},{"key":"705_CR14","doi-asserted-by":"crossref","unstructured":"Caskey JR, Kaufman D. Dual biologic therapy in a patient with severe asthma and other allergic disorders. BMJ Case Rep. 2021;14(5):e242211.","DOI":"10.1136\/bcr-2021-242211"},{"issue":"8","key":"705_CR15","doi-asserted-by":"publisher","first-page":"100669","DOI":"10.1016\/j.waojou.2022.100669","volume":"15","author":"KC Bergmann","year":"2022","unstructured":"Bergmann KC, Oestmann JW, Bousquet J, Zuberbier T. Successful simultaneous targeting of IgE and IL-5 in a severe asthmatic patient selected for lung transplantation. World Allergy Organ J. 2022;15(8):100669.","journal-title":"World Allergy Organ J"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"587621","DOI":"10.3389\/fphar.2020.587621","volume":"11","author":"C Domingo","year":"2020","unstructured":"Domingo C, Pomares X, Moron A, Sogo A. Dual monoclonal antibody therapy for a severe asthma patient. Front Pharmacol. 2020;11:587621.","journal-title":"Front Pharmacol"},{"key":"705_CR17","doi-asserted-by":"publisher","unstructured":"Kwon IJ, Kim T, Yoo DS, Min S, Kim SC, Kim JH. Clinical effect of Omalizumab as an adjuvant treatment to rituximab in patient with refractory bullous pemphigoid. J Dermatol. 2022. https:\/\/doi.org\/10.1111\/8138.16678.","DOI":"10.1111\/8138.16678"},{"issue":"18","key":"705_CR18","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.2217\/imt-2020-0203","volume":"12","author":"L Diluvio","year":"2020","unstructured":"Diluvio L, Vollono L, Zangrilli A, et al. Omalizumab and adalimumab: a winning couple. Immunotherapy. 2020;12(18):1287\u201392.","journal-title":"Immunotherapy"},{"key":"705_CR19","doi-asserted-by":"publisher","unstructured":"Abdelmaksoud A, Temiz SA, Daye M, et al. Response of chronic refractory psoriasis vulgaris with urticaria to combined Secukinumab and Omalizumab: a case report and review of the literature. J Cosmet Dermatol. 2022.\u00a0https:\/\/doi.org\/10.1111\/jocd.15551.","DOI":"10.1111\/jocd.15551"},{"key":"705_CR20","doi-asserted-by":"publisher","first-page":"611549","DOI":"10.3389\/fimmu.2020.611549","volume":"11","author":"SM Seyed Jafari","year":"2020","unstructured":"Seyed Jafari SM, Feldmeyer L, Bossart S, Simon D, Schlapbach C, Borradori L. Case report: combination of Omalizumab and dupilumab for recalcitrant bullous pemphigoid. Front Immunol. 2020;11:611549.","journal-title":"Front Immunol"},{"issue":"10","key":"705_CR21","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1080\/17512433.2022.2120469","volume":"15","author":"B Zhou","year":"2022","unstructured":"Zhou B, Dong J, Liang S, Shang S, Li L. The changes of IgE levels in type 2 inflammatory diseases after treatment of dupilumab: a systematic review and meta-analysis. Expert Rev Clin Pharmacol. 2022;15(10):1233\u201342.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"705_CR22","doi-asserted-by":"publisher","first-page":"983852","DOI":"10.3389\/fimmu.2022.983852","volume":"13","author":"G Kardas","year":"2022","unstructured":"Kardas G, Panek M, Kuna P, Damianski P, Kupczyk M. Monoclonal antibodies in the management of asthma: dead ends, current status and future perspectives. Front Immunol. 2022;13:983852.","journal-title":"Front Immunol"},{"issue":"2","key":"705_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000447692","volume":"170","author":"D Bagnasco","year":"2016","unstructured":"Bagnasco D, Ferrando M, Varricchi G, Passalacqua G, Canonica GW. A critical evaluation of Anti-IL-13 and Anti-IL-4 strategies in severe asthma. Int Arch Allergy Immunol. 2016;170(2):122\u201331.","journal-title":"Int Arch Allergy Immunol"},{"issue":"3","key":"705_CR24","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.jaip.2022.11.044","volume":"11","author":"G Brusselle","year":"2022","unstructured":"Brusselle G, Quirce S, Papi A, Kuna P, Chipps BE, Hanania NA, et al. Dupilumab Efficacy in patients with uncontrolled or oral corticosteroid-dependent allergic and nonallergic asthma. J Allergy Clin Immunol Pract. 2022;11(3):873\u2013884.e11. https:\/\/doi.org\/10.1016\/j.jaip.2022.11.044.","journal-title":"J Allergy Clin Immunol Pract."},{"key":"705_CR25","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2021.01.004","volume":"232","author":"SE Kang","year":"2021","unstructured":"Kang SE, Park JK, Yoo HJ, Kang HS, Park YW, Park BC, et al. Efficacy of novel bispecific antibody targeting TNF-alpha\/CXCL10 in the treatment of experimental arthritis. Transl Res. 2021;232:75\u201387.","journal-title":"Transl Res"},{"key":"705_CR26","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.biopha.2017.02.045","volume":"89","author":"Y Wang","year":"2017","unstructured":"Wang Y, Wu Q, Liu Z, Guo X, Zhou L, Song L, et al. A Recombinant IgG-like bispecific antibody acting as interleukin-1beta and interleukin-17A inhibitor exhibits a promising efficacy for rheumatoid arthritis. Biomed Pharmacother. 2017;89:426\u201337.","journal-title":"Biomed Pharmacother"},{"key":"705_CR27","doi-asserted-by":"publisher","unstructured":"Krakowski AC, Senft SC, Heymann WR. Demodex folliculitis and recent dupilumab administration. Pediatrics. 2021;147(5).\u00a0https:\/\/doi.org\/10.1542\/peds.2020-029520.","DOI":"10.1542\/peds.2020-029520"},{"issue":"4","key":"705_CR28","doi-asserted-by":"publisher","first-page":"e13770","DOI":"10.1111\/pai.13770","volume":"33","author":"C Matucci-Cerinic","year":"2022","unstructured":"Matucci-Cerinic C, Viglizzo G, Pastorino C, Corcione A, Prigione I, Bocca P, et al. Remission of eczema and recovery of Th1 polarization following treatment with dupilumab in STAT3 hyper IgE syndrome. Pediatr Allergy Immunol. 2022;33(4):e13770.","journal-title":"Pediatr Allergy Immunol"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-025-00705-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-025-00705-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T17:08:58Z","timestamp":1744218538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcimmunol.biomedcentral.com\/articles\/10.1186\/s12865-025-00705-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,8]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/s12865-025-00705-8","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,8]]},"assertion":[{"value":"29 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study adhered to the declaration of Helsinky and was approved by the Institutional Review Board of Hadassah Medical Center (IRB number: HMO-0729-22). The board allowed for a waiver of signed, informed consent from patients.This study was approved by an institutional review board of Hadassah Medical Center (IRB # HMO-0792-22).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}